Tee Labs Incubated | Degron Therapeutics Cracks the “Undruggable” Bottleneck of HuR, Publishing Landmark Breakthrough in Nature
June 10, 2026 — Degron Therapeutics, a clinical-stage biotechnology company dedicated to the development of novel molecular glue degrader drugs, announced today that its collaborative research with ShanghaiTech University has been published in the premier international scientific journal Nature. The study reports for the first time the molecular regulatory mechanisms of a novel molecular glue degrader targeting the RNA-binding protein HuR (Human antigen R) in BRAF-mutated tumors, establishing a mechanistic foundation for the clinical indication selection of Degron Therapeutics’ HuR molecular glue candidates.
Starting from a glutarimide ring chemical scaffold known to bind CRBN (Cereblon), Degron Therapeutics systematically appended diverse chemical side chains at various positions of this scaffold to engineer its proprietary GlueXplorer® molecular glue degrader discovery platform. In theory, each newly synthesized compound can create a distinct binding interface on the surface of CRBN, thereby conferring the potential to recruit and selectively degrade distinct neo-substrate proteins.
Subsequently, the research team treated cancer cells with this compound library and employed high-throughput quantitative proteomics mass spectrometry to systematically screen and identify proteins undergoing specific degradation. One round of screening revealed a dramatic reduction in levels of the RNA-binding protein HuR, highlighting it as the most promising degradation target. Following downstream validation, the team ultimately identified a novel class of molecular glue degraders capable of potently and selectively degrading HuR.
Figure 1. Structural model illustrating molecular glue-induced recruitment and degradation of HuR by the E3 ubiquitin ligase CRBN, thereby regulating BRAF alternative RNA splicing
Through in-depth mechanistic investigation, the team discovered that depletion of HuR directly disrupts the post-transcriptional processing of the core oncogene BRAF. Precursor messenger RNA (pre-mRNA) of BRAF requires precise alternative splicing to generate functional proteins. In this cascade, HuR acts as a crucial “splicing quality overseer”—upon loss of HuR, aberrant splicing of BRAF pre-mRNA ensues, preventing the production of functional BRAF oncoprotein.
BRAF protein plays an essential oncogenic driver role in cancers harboring mutations such as BRAF V600E, particularly in colorectal cancer (CRC). Although BRAF inhibitors have been developed and approved clinically, they frequently induce paradoxical BRAF dimerization and feedback activation of upstream EGFR, which subsequently reactivates the MAPK (mitogen-activated protein kinase) signaling cascade, driving secondary drug resistance and treatment failure.
Figure 2. Mechanistic schematic depicting HuR molecular glue degraders regulating BRAF alternative splicing to downregulate BRAF protein, demonstrating synergy with BRAF, EGFR, or MEK inhibitors
Leveraging this original breakthrough, Degron Therapeutics rapidly accelerated translation, developing DEG6498, the world’s first-in-class molecular glue degrader targeting HuR. From initial bench discovery to receiving Investigational New Drug (IND) approvals from both the U.S. FDA and China’s National Medical Products Administration (NMPA), the team accomplished this high-efficiency “bench-to-bedside” translation in approximately five years.
This study not only brings renewed therapeutic hope to patients with relapsed or refractory BRAF-mutated colorectal cancer, but its successful “phenotype-driven, reverse discovery” paradigm also provides an innovative blueprint for tackling previously “undruggable” targets, signifying that China’s targeted protein degradation (TPD) drug development has entered the global vanguard.
About DEG6498
DEG6498 is a potent, orally bioavailable small-molecule molecular glue degrader that induces proximity and ternary complex formation between the E3 ubiquitin ligase substrate receptor Cereblon (CRBN) and the RNA-binding protein Human antigen R (HuR), driving targeted proteasomal degradation of HuR.
DEG6498 is the first-in-class drug candidate targeting HuR to enter clinical development and is currently undergoing Phase I clinical evaluation in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT07244835 / Chinadrugtrials.org.cn Registration: CTR20254261).
About Degron Therapeutics
Degron Therapeutics is a clinical-stage biotechnology company committed to discovering and developing novel therapies through its proprietary molecular glue-based targeted protein degradation (TPD) platform to benefit human health.
The company’s unique GlueXplorer® platform encompasses a rapidly expanding, IP-protected chemical library and screening engine designed to engineer a new class of small-molecule therapeutics targeting high-value disease drivers, including historically “undruggable” proteins. Degron has successfully advanced proprietary first-in-class (FIC) molecular glue degrader programs to IND approvals in both the United States and China, progressing them into clinical development. The company’s R&D pipeline is continuously expanding across oncology, inflammation, metabolic disorders, and rare diseases. Degron operates offices and research facilities in Shanghai, Hangzhou, and San Diego, California.
For more information, please visit: www.degrontx.com.
About Tee Labs
Tee Labs is an international incubator and innovation community co-founded by seasoned entrepreneurs and venture capitalists, dedicated to advancing pioneering frontiers in medicine—including novel drug R&D, diagnostics, and personalized medicine powered by artificial intelligence and digital solutions.
We provide comprehensive support covering laboratory infrastructure, corporate functions, integrated supply chain and service channels, and venture capital, deeply empowering early-stage founding teams and accelerating company R&D cycles. The facilities are fully outfitted with foundational, general-purpose laboratory instrumentation alongside a shared equipment platform, substantially curtailing the startup phase for workspace and equipment procurement so that founders can focus entirely on core R&D milestones.
Currently, Tee Labs features approximately 2,600 square meters of incubation space, including 1,500 square meters of dedicated laboratory facilities covering chemistry, molecular biology, cell culture, microbial/bacterial culture, and Biosafety Level 2 (BSL-2) laboratories. These versatile, multi-type laboratory suites accommodate diverse research pipelines, providing early-stage ventures with the rare advantage of housing multidisciplinary teams within a single cohesive workspace.
